OBJECTIVES: To estimate the budget impact of inotuzumab ozogamicin (InO) for treatment of adults with relapsed or refractory b-cell acute lymphoblastic leukemia (LAL) from the Algerian healthcare system perspective.

METHODS: A BIM was developed to compare treatment and hospital-stay costs of two scenarios (with and without InO) over a one-year period. The annual eligible population was estimated using local data from the National Office of Statistics and a national study on LAL incidence¹. Blinatumomab was considered as the sole comparator: it was assumed that Blina had all the market in the base case, whilst InO and Blina covered half the market each in the alternative scenario. The treatment costs were calculated based on a 2 cycles treatment duration for both Blina² and InO³. No vial sharing between patients was assumed. Duration of hospitalization was derived from the treatments’ SmpC and RWD. The costs of hospital stay were obtained from literature and all costs were reported in Euros. A one-way sensitivity analysis was conducted to assess the impact of the variability of relevant model inputs.

RESULTS: The BIA of InO in the Algerian market indicates a saving of more than 800k€ over the first year of treatment, a decrease of 24% compared to the base case scenario. InO was demonstrated to be cost saving in the base case, and for most input ranges in the sensitivity analysis. The LAL annual incidence in Algeria and the number of treatment cycles were shown to be the most influential inputs. Cost savings could be substantially larger if incidence of LAL is higher vs. local point estimates used in the base case.

CONCLUSIONS: The introduction of InO is expected to generate savings on treatment and hospitalization costs while improving patient convenience by reducing duration of hospital stay.